Drug Profile
Research programme: protein therapeutics - Ansun Biopharma
Alternative Names: ANSX109/142; ANSX98; Sepcidin; ViradinLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator NexBio
- Developer Ansun Biopharma
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Sepsis; Septic shock; Viral haemorrhagic fevers
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Bacterial infections in USA (IV)
- 23 Feb 2023 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (IV)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)